Chemotherapy nave patients with unresectable MPM were stratified by histology and performance status , and randomized 2:1 to pemetrexed/cisplatin plus CBP501 25mg/m ( 2 ) IV ( Arm A ) or pemetrexed/cisplatin alone ( Arm B ) .